The company is relieving all its staff who were directly engaged by our US subsidiary in its plant in connection with the manufacturing process in a phased manner
The summit to demonstrate revolutionary techniques and advanced medical procedures for treating CTO
DEP® ADCs exploit the unique potential of Starpharma's DEP® technology to provide enhanced characteristics to ADCs i
OrderPoint was designed as an advanced DTR solution from its first release in 2016.
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
The Trial, the first of its kind in Israel, recently obtained approval from the Israeli Ministry of Health and is preparing for participant recruitment.
The estimated capex is to the tune of Rs. 140 crore to be funded through debt and internal accrual
Collaboration focuses on developing and implementing real-world research to drive patient access to cancer medicines
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions
Subscribe To Our Newsletter & Stay Updated
